Loading
A phase 2 trial of Belantamab mafodotin, Dexamethasone, Pomalidomide in multiple myeloma, run by GlaxoSmithKline, now recruiting.
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) is a phase 2 interventional study registered as NCT07227311 by GlaxoSmithKline, with 200 participants planned, started 2026-04-15 and due to reach its primary completion in 2030-08-30. Interventions recorded: Belantamab mafodotin, Dexamethasone, Pomalidomide, Bortezomib, Carfilzomib. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Belantamab mafodotin, Pomalidomide, Bortezomib, GSK.
Shares Belantamab mafodotin, Pomalidomide, GSK, Dexamethasone.
Shares Belantamab mafodotin, Bortezomib, GSK, Dexamethasone.
Shares Belantamab mafodotin, Bortezomib, GSK, Dexamethasone.
Shares Belantamab mafodotin, GSK, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.
Shares Belantamab mafodotin, Pomalidomide, GSK, Dexamethasone.